March 12, 2014 9:47 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Wednesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: CMRX), but removed the $34.00 price target.In the report, Morgan Stanley noted, “Chimerix announced today that based on urgent patient need, they have negotiated with the FDA to immediately start an open label 20 pt adenovirus (AdV) trial. Furthermore, the company notes that the FDA has agreed to work with them towards expanding this open label trial into a more comprehensive, pivotal Ph 3 AdV trial. We view this as a good outcome for the company and pts, and reinforces our view that this drug likely has broader potential beyond the recent focus on CMV prevention in high risk stem cell transplants (SCT).”Chimerix closed on Tuesday at $20.80.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.